In Vivo Properties of Oncostatin M

Annals of the New York Academy of Sciences

Volumn 762, Issue 1, 1995, Pages 42-54

  WALLACE, PHILIP M ^a   MACMASTER, JOHN F ^a   RILLEMA, JILL R ^a   ROULEAU, KATHERINE A ^a   HANSON, MARCIA B ^a   BURSTEIN, SAMUEL A ^b   SHOYAB, MOHAMMED ^c  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; INTERLEUKIN 11; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD CELL COUNT; CONFERENCE PAPER; DEVELOPMENT; HEMATOPOIESIS; HOMEOSTASIS; INFLAMMATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0029153654     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1995.tb32313.x     Document Type: Article

References (74)

1. Oncostatin M: A growth regulator produced by differentiated histiocytic lymphoma cells
2. Oncostatin M is a member of a cytokine family that includes leukemia‐inhibitory factor, granulocyte colony‐stimulating factor, and interleukin 6
3. Structural design and molecular evolution of a cytokine receptor super‐family
4. Cardiotrophin1, a novel cytokine that induces cardiac myocyte hypertrophy
5. A receptor‐mediated pathway for cholesterol homeostasis
6. Are LIF and related cytokines functionally equivalent
7. Localization of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing's sarcoma breakpoint
8. Tandem linkage of genes coding for leukemia inhibitory factor (LIF) and oncostatin M (OSM) on human chromosome 22
9. The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22
10. Close proximity of the genes for leukemia inhibitory factor and oncostatin M
11. Biological and clinical aspects of interleukin 6
12. Enhancement of in vitro and in vivo antigen‐specific antibody responses by interleukin 11
13. Cytokine receptors and signal transduction
14. Neuropoietic cytokines in the hematopoietic fold
15. The alpha component of the CNTF receptor is required for signaling and defines potential CNTF targets in the adult and during development
16. Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor
17. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL‐6 signal transducing receptor component gp130
18. Proliferative responses and binding properties of hematopoietic cells transfected with low‐affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor
19. Interleukin‐6 signal transducer gp130 mediates oncostatin M signaling
20. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130
21. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily
22. Oncostatin M, leukemia inhibitory factor, interleukin 6 induce the proliferation of human cells via the common signal transducer, GP130
23. Interactions between Oncostatin M and the IL‐6 signal transducer, gp130
24. Oncostatin M binds the high‐affinity leukemia inhibitory factor receptor
25. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signal through partially shared receptor complexes
26. Reconstitution of the response to leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in hepatoma cells
27. Identification and characterization of cellular receptors for the growth regulator, oncostatin M
28. Oncostatin M is a differentiation factor for myeloid leukemia cells
29. The IL‐6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor
30. Oncostatin M binds directly to gp130 and behaves as interleukin6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors
31. The oncostatinM specific receptor: Cloning of a novel subunit related to the LIF receptor
32. Mitogen‐activated protein kinases and ribosomal S6 protein kinases are involved in signaling pathways shared by interleukin‐11, interleukin‐6, leukemia inhibitory factor, and oncostatin M in mouse 3T3‐L1 cells
33. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the IL‐6 signal transducer GP‐130
34. Identification of a major growth factor for AIDS‐Kaposi's sarcoma cells as oncostatin M
35. Regulation of cell growth by recombinant oncostatin M
36. Oncostatin M as a potent mitogen for AIDS‐Kaposi's sarcoma‐derived cells
37. Oncostatin M stimulates proliferation in B9 hybridoma cells: Potential role of oncostatin M in plasmacytoma development
38. Oncostatin M is a mitogen for rabbit vascular smooth muscle cells
39. Oncostatin M up‐regulates low density lipoprotein receptors in HepG2 Cells by a novel mechanism
40. Oncostatin M: A novel regulator of endothelial cell properties
41. Oncostatin M stimulates urokinase‐type plasminogen activator activity in human synovial fibroblasts
42. Regulation of granulocyte colony‐stimulating factor and granulocyte‐macrophage colony‐stimulating factor expression by Oncostatin M
43. Regulation of IL‐6 expression by oncostatin M
44. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro
45. The role of Oncostatin M in the acute phase response
46. Oncostatin M (OSM) inhibits the differentiation of pluripotent embryonic cells in vitro
47. Selective regulation of metalloproteinase inhibitor (TIMP‐1) by oncostatin M in fibroblasts in culture
48. Interaction between oncostatin M, interleukin 1 and prostaglandin E2 in induction of IL‐6 expression in human fibroblasts
49. Amplification and expression of heterologous oncostatin M in Chinese hamster ovary cells
50. Macrophage‐derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells
51. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells
52. Plasma clearance, organ distribution and target cells of interleukin‐6/hepatocyte‐stimulating factor in the rat
53. Clearance and fate of leukemia‐inhibitory factor (LIF) after injection into mice
54. Ciliary neurotrophic factor: Pharmacokinetics and acute‐phase response in rat
55. Thrombocytopoiesis in normal and sublethally irradiated dogs: Response to human interleukin‐6
56. Hematologic effects of recombinant human interleukin‐6 in dogs exposed to a total‐body radiation dose of 2.4 Gy
57. A phase I trial of intravenous interleukin‐6 in patients with advanced cancer
58. TM rhIL‐11 growth factor; rhIL‐11) prevents thrombocytopenia following chemotherapy (CT) with cyclophosphamide (C) and doxorubicin (A) in women with breast cancer (BC)
59. The in vivo effects of subcutaneously (SC) administered recombinant human interleukin‐11 (Neumegacgo rhIL‐11 growth factor; rhIL‐11) in women with breast cancer (BC)
60. The acute phase response
61. Interleukin‐6 and the acute phase protein
62. Induction of rat acute‐phase proteins by interleukin 6 in vivo
63. Impaired immune and acute‐phase responses in interleukin‐6‐deficient mice
64. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases
65. Purification and characterization of cytostatic lymphokines produced by activated human T lymphokines
66. Growth factors affecting human thrombocytopoiesis: Potential agents for treatment of thrombocytopenia
67. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation
68. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor
69. Distruption of the CNTF gene results in motor neuron degeneration
70. The major acute phase reactants: C‐reactive protein, serum amyloid P component and serum amyloid A protein
71. Deletions on chromosome 22 in sporadic meningioma
72. Analysis of chromosome‐22 loci in meninglioma—Alterations in the leukemia inhibitory factor (LIF) locus
73. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro